Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dova Pharmaceuticals, Inc.

http://www.dova.com

Latest From Dova Pharmaceuticals, Inc.

Sobi’s Doptelet Disappoints In Large New Indication

A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations. 

Clinical Trials Companies

Verona Stock Soars After $200m Placement For COPD Drug

The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.

Financing Respiratory

Verona Details COPD Opportunity For Ensifentrine

Verona Pharma’s candidate COPD therapy ensifentrine has a first-in-class dual mechanism of action and is to be explored as an add-on to LAMA and LABA therapy in two Phase III clinical studies.

Clinical Trials Respiratory

Sobi Reaps Benefits From Acquisitions, Commercial Focus

Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.

Sales & Earnings Deals
See All

Company Information

  • Other Names / Subsidiaries
    • AkaRx, Inc.
    • PBM Capital Group
UsernamePublicRestriction

Register